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Abstract
We analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and 
association with overall survival (OS) for Bacterial blood stream infections (BSIs) occurring 
within 100 days of alloHCT in 2 different phases: pre/peri engraftment (BSI very early phase, 
BSI-VEP) and BSI post engraftment (BSI occurring between 2 weeks after engraftment and 
Day100, late early phase, BSI-LEP). Of 7,128 alloHCT patients, 2,656 (37%) had ≥1 BSI by 
day100. BSI-VEP, BSI-LEP, BSI-Both constituted 56% (n=1492), 31% (n=824), and 13% (n=340) 
of total BSI, respectively. Starting in 2009 we observed a gradual decline in BSI incidence through 
2012 (61% to 48%). Patients with BSI-VEP were more likely to receive a myeloablative 
conditioning (MAC) regimen with total body irradiation (TBI). NRM was significantly higher in 
patients with any BSI (RR 1.82 95CI 1.63–2.04 for BSI-VEP, RR 2.46, 95%CI 2.05–2.96 for BSI-
LEP, and RR 2.29, 95%CI 1.87–2.81 for BSI-Both) compared with those without BSI. OS was 
significantly lower in patients with any BSI compared with patients without BSI (RR 1.36, 95%CI 
1.26–1.47 for BSI-VEP; RR 1.83, 95%CI 1.58–2.12 for BSI-LEP: RR 1.66, 95%CI 1.43–1.94 for 
BSI-Both). BSIs within day100 after alloHCT are common and remain a risk factor for mortality.
Keywords
Bacterial stream infections; allogeneic hematopoietic cell transplantation; engraftment; mortality
Introduction
Bacterial blood stream infections (BSIs) are common after allogeneic hematopoietic cell 
transplantation (alloHCT), occurring in 20 to 45% of patients.1–7 The main predisposing 
factor for pre-engraftment BSI are mucosal injury (mucosal barrier injury laboratory-
confirmed bloodstream infection, MBI- LCBI)8 or the presence of an indwelling central 
catheter (central line-associated BSI, CLABSI)9. Higher incidence of BSI has been reported 
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for umbilical cord blood (UCB),6,10 or bone marrow7 allografts (compared with peripheral 
blood), unrelated donors1,6 (compared with related), HLA-mismatched donors11 (compared 
with mismatched), myeloablative conditioning12 (compared with nonmyeloablative 
conditioning) and advanced leukemia1. In addition, graft-versus-host disease (GVHD),5 and 
steroid use,13,14 have been associated with higher BSI incidence. In single center studies, 
BSI is associated with increased mortality at 1 year after alloHCT.6,11,14,15
We analyzed the registry data from the Center for International Blood and Marrow 
Transplant Research (CIBMTR) to assess the impact of early BSI (by day 100) on transplant 
outcomes including overall survival (OS), non-relapse mortality (NRM), disease-free 
survival (DFS) and relapse at 1 year after alloHCT. Two BSI time-frames were examined: 
pre/peri-engraftment phase [Very Early Phase (VEP)], and post-engraftment phase, 2 weeks 
after engraftment through day 100 [Late Early Phase (LEP)]. Transplant outcomes for 
patients with BSI-VEP, BSI-LEP, and both BSIs were compared with patients without BSI.
Material and Methods
Study Population
The study population included all patients receiving first alloHCT for acute myeloid 
leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome 
(MDS) in pediatric and adult patients between January 2008 and December 2012. Grafts 
from related (including haploidentical) and unrelated (URD) donors were included. Graft 
sources included bone marrow (BM), peripheral blood stem cells (PBSC), and UCB. T cell 
depleted grafts were also included. Patients who had a prior alloHCT were excluded.
Data Source
The CIBMTR is a voluntary working group of more than 450 transplantation centers 
worldwide that contribute detailed data on consecutive hematopoietic cell transplants to a 
statistical center located at the Medical College of Wisconsin in Milwaukee and the National 
Marrow Donor Program (NMDP) Coordinating Center in Minneapolis. Participating centers 
are required to report all transplantations consecutively; compliance is monitored by onsite 
audits. The CIMBTR maintains an extensive database of detailed patient-, transplant-, and 
disease-related information, and prospectively collects data longitudinally with yearly 
follow-ups. Observational studies conducted by the CIBMTR are performed in compliance 
with HIPAA regulations as a public health authority and also in compliance with all 
applicable federal regulations pertaining to the protection of human research participants, as 
determined by a continuous review by the Institutional Review Boards of NMDP and the 
Medical College of Wisconsin. The CIBMTR collects data at two levels: Transplant 
Essential Data (TED) and Comprehensive Report Form (CRF) data. TED data include 
disease type, age, gender, pre-transplant disease stage and chemotherapy-responsiveness, 
date of diagnosis, graft type (bone marrow- and/or blood-derived stem cells), conditioning 
regimen, post-transplant disease progression and survival, development of a new malignancy 
and cause of death. All CIBMTR centers contribute TED data. CRF data are collected on a 
subset of registered patients, selected by weighted randomization. CRF data include more 
detailed disease and pre- and post-transplant clinical information, including infection data. 
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TED and CRF level data are collected pre-transplant, 100 days and six months post-HCT 
and annually thereafter or until death. This analysis includes only CIBMTR CRF data.
Infection Data
Data for infections are captured on the CRF using an organism code, site of infection, and 
date of infection. BSI was defined as the isolation of a bacterial pathogen from the blood/
buffy coat obtained from peripheral blood or a central venous catheter. Patients from 50 
centers (n=268) were excluded from the analysis due to the center reporting 100% of 
patients with BSI, 0% of patients with BSI, or 100% of BSI due to coagulase negative 
Staphylococcus spp. BSI was considered “recurrent” if there was at least 7 days between the 
dates of reported infection for the same organism. Data regarding antibacterial prophylaxis, 
treatment and infection severity are not collected in the registry and, therefore, unavailable 
for analyses.
Definitions
Bacterial BSI was analyzed from day −10 (D-10) through 100 days after transplant (D100). 
BSI reported after D100 was not included in the analyses. Based on onset of BSI relative to 
neutrophil recovery, BSIs were grouped into pre/peri- and post-neutrophil engraftment. Pre/
peri-engraftment or very early phase (“BSI-VEP”) BSI was defined as infection occurring 
between D-10 through 14 days after neutrophil engraftment. Post-engraftment or late early 
phase (“BSI-LEP”) BSI was defined as infection occurring between 15 days after neutrophil 
engraftment until D100. Patients with both BSI-VEP and BSI-LEP were designated as “BSI-
Both”. Patients who did not develop any BSI by D100 are defined as “no BSI” and served as 
the control population. Recurrent bacterial infections required a minimum of 7 days between 
cultures with the same organism reported. Neutrophil engraftment was defined as the first of 
3 consecutive days with an absolute neutrophil count ≥ 500/mm3. Platelet engraftment was 
defined as a platelet count ≥20,000/mm3 without platelet transfusions in the prior 7 days. 
Acute and chronic GVHD was scored by standard criteria.16–18 The use of growth factors 
between day −3 through day 15 post-transplant was collected.
Statistics
Patient-, disease-, and transplant –related factors were compared between groups using the 
Chi-square test for categorical variables and Wilcoxon two-sample testing for continuous 
variables. Time-dependent variables (neutrophil and platelet engraftment and acute GVHD) 
occurring after transplant and prior to d100 are descriptive only since these events occurred 
variably by patient in relation to the bacterial BSI event that categorized the cohorts. 
Probabilities of OS and DFS were calculated using the Kaplan-Meier estimator. Values for 
relapse and NRM were generated using cumulative incidence estimates to account for 
competing risks. Because the patient populations are determined by an event occurring (or 
not) by D100, we performed univariate analyses for both the entire population from the time 
of transplant (D0) as well as a left-truncated analysis for only those patients alive at D100 
(data not shown). As trends and statistical significance for all events were the same, this 
manuscript reports the results for the entire population unless otherwise specified. A Cox 
model for the entire population was fit to determine factors important for OS, DFS, relapse, 
and NRM and the main effect variable was the time-dependent variable of no BSI 
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(reference) versus BSI-VEP versus BSI-LEP versus BSI-both forced into every model. The 
proportional hazards assumption was checked; when violated, the co-variate was included as 
a time-dependent covariate. Center effect was tested using the score test of Commenges and 
Andersen.19 If there is found to be a center effect, then the results are adjusted accordingly 
to account for this. Variables examined in the multivariable models included: age (≤ 20 years 
vs 21 – 40 years vs 41 – 50 years vs >60 years); Karnofsky performance status (≥ 90% vs 
<90%); Disease stage (AML/ALL early (CR1) vs AML/ALL intermediate (≥CR2) vs 
AML/ALL Advanced (relapsed/refractory), vs MDS early (RA, RARS, RCMD, RCMD/RS) 
vs MDS Advanced (RAEB1, RAEB2)); HCT-CI (0 vs 1 – 2 vs ≥3); donor/recipient CMV 
serostatus (both negative vs any positive); Conditioning intensity (myeloablative vs non-
myeloablative/reduced intensity); Donor/HLA-Match (HLA-identical sibling vs 8/8 
unrelated vs mismatched unrelated vs UCB vs other [mismatched related/Haploidentical or 
unrelated with HLA missing]); ATG/Campath use (no vs yes); GVHD prophylaxis 
(calcineurin inhibitor [CNI]+ methotrexate ± others vs. CNI + mycophenylate mofetil ± 
others vs. T-cell depletion [in vivo or ex vivo] vs. Other); and year of HCT (2008 – 2009 vs 
2010 – 2012). Due to clinical suspicion of an impact of acute GVHD and its therapy on the 
development of BSI and transplant outcomes, separate Cox models were fit forcing in the 
co-variate of development of acute GVHD at any time, aGVHD occurring prior to the 
development of the BSI, and without acute GVHD in the model. Important co-variates, 
relative risks, and statistical significance were unchanged between these three models for all 
transplant outcomes; therefore, the models shown do not include acute GVHD.
Results:
Blood stream infections (BSIs)
Of total 7,128 alloHCT, 2,656 (37%) had ≥1 BSI by D100 (Table 1). Of these 2,656 patients, 
1891 (71%) had one BSI [762 (66%) by one single organism and 129 (5%) by >1 organisms 
(polymicrobial)] and 765 (29%) had >1 BSIs. (Figure 1 and Supplemental Table 1). BSI-
VEP comprised 56% of total BSI (n=1492); BSI-LEP or BSI-Both comprised 31% (n=824) 
and 13% (n=340), respectively.
The median time to first BSI-VEP was 7 days (range, D-1 to D74); and the median time to 
first BSI-LEP was 58 days (range, D21 to D100) (Table 2). Staphylococcus species (spp.) 
were the most common bacteria, and coagulase negative Staphylococcus (CoNS) accounted 
for over a quarter (n=647; 28%) of the infections reported (Figure 1A, Supplemental Table 
1).
Of note, for the entire population the cumulative incidence by day 100 of fungal infection 
(any reported) was 8% and that of viral infections (any reported) was 44%. Because of the 
issues of timing of 3 time-dependent variables (BSI vs. fungal vs. viral) for infection and the 
added complication of the time-dependent of aGVHD, this was not statistically compared 
across the BSI groups.
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Comparison of Factors Amongst BSI Groups
Patients with no BSI were older, had more early stage disease at the time of alloHCT, were 
more likely to receive a reduced-intensity conditioning (RIC) regimen with an HLA-
identical sibling PBSC donor using tacrolimus and methotrexate for GVHD prophylaxis, and 
were less likely to receive TBI-based conditioning or post-transplant granulocyte colony 
stimulating factor (GCSF) (Table 1). Patients with BSI-VEP were more likely to receive a 
myeloablative conditioning (MAC) regimen with total body irradiation (TBI) (Table 1). 
White blood cell count (WBC), absolute neutrophil count (ANC) at the time of alloHCT, or 
history of clinically significant fungal infection prior to alloHCT were similar across the 4 
groups.
Table 2 reports the time-dependent events of engraftment and GVHD among the four BSI-
defined, patient cohorts. As cohorts were defined by BSI developing before neutrophil 
engraftment and/or by D100 and platelet engraftment and acute GVHD generally occurred 
prior to D100, it is not possible to formally compare by univariate analysis the cumulative 
incidence of acute GVHD and platelet engraftment across the cohorts. When assessing only 
patients who were alive at 100 days, the cumulative incidence of chronic GVHD was similar 
at 1 year for the four cohorts [BSI-VEP: 45% (42 – 48%) vs BSI-LEP: 43% (39 – 47%) vs 
BSI-both: 44% (38 – 50%) vs no BSI: 46% (45 – 48%); p = .2007].
Survival
NRM was significantly higher in patients with any BSI compared with those with no BSI in 
multivariable analyses (Table 3, Figure 2). NRM was lower for BSI-VEP compared with 
BSI-LEP (HR, 0.74; 95% CI: 0.57–0.97, p=0.003) and BSI-Both (HR, 0.80; 95% CI: 0.67–
1.0, p=0.03).
DFS was lower for BSI-VEP, BSI-LEP or BSI-both compared with no BSI; and BSI-LEP or 
BSI-Both had the lowest DFS among these groups. Relapse was similar among the 4 groups.
OS was significantly lower in patients with any BSI compared with patients without BSI 
(Table 3, Figure 3). However, OS was higher for BSI-VEP compared with BSI-LEP (HR, 
0.74; 95%CI: 0.62–0.90, p<0.0001) and BSI-Both (HR, 0.82; 95%CI: 0.64–1.06, p=0.008). 
Besides infections, graft failure or organ failure were more important in BSI-VEP patients 
whereas GVHD was more common in BSI-LEP and BSI-Both as a cause of NRM. 
(Supplemental Table 2). Of note, in all subgroups, relapse was the most common cause of 
death.
In multivariate analyses, additional factors associated with higher NRM and lower OS were 
older age, lower KPS, higher HCT-CI score (≥3), advanced acute leukemia, CMV 
seropositivity in either the donor or the recipient, use of alternative donor (HLA-mismatched 
URD, UCB or other donor) and earlier transplantation (Table 3). In addition, MDS was 
associated with a higher NRM.
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Discussion:
We analyzed the CIBMTR registry data to assess the impact of early BSI (by D100) on long 
term (by D365) transplant outcomes. Our cohort consists of >7,000 patients from 181 
Centers who received alloHCT between from 2008 through 2012. This is to our knowledge 
the largest analysis examining the impact of BSI after HCT in the contemporary era. Our 
main findings are that 1) Patients with BSI by D100 after alloHCT had increased NRM and 
lower OS compared with patients without BSI. 2) BSI-LEP was associated with increased 
NRM compared with no BSI or BSI-VEP.
Consistent with single center studies3,20, the majority of BSI occurred in the pre/peri 
engraftment phase (i.e., BSI-VEP). However, the risk for mortality was higher for patients 
with BSI-LEP and for patients with both BSI-VEP and BSI-LEP. Interestingly, both in 
univariate and multivariable analyses, the increased NRM was similar for those with BSI-
LEP and the cohort with both BSI-VEP and BSI-LEP. We postulate that differences in 
mortality could be partially explained by different risk factors and causative organisms 
between VEP and LEP BSIs. Patients with BSI-VEP were more likely to have received 
MAC that are associated with more severe and protracted mucosal injury and longer time to 
neutrophil engraftment. As a result, BSI-VEP were predominantly caused by pathogens 
found in gastrointestinal (GI) flora BSI (e.g., Enterobacteriaceae spp., anaerobes). In 
contrast, patients with BSI-LEP were more likely to have received RIC regimens associated 
with later onset GVHD. BSI-LEP were predominantly caused by skin organisms (e.g., 
coagulase-negative Staphylococci, CoNS) suggesting possibly related to central venous 
catheter (CVC) use. While in general skin organisms are associated with low pathogenity 
(with exception of S. aureus) such organisms may be a surrogate marker of increased 
morbidity and more frequent utilization of health care centers. Alternatively, although 
difficult to prove, it is possible that monitoring and reacting to patients may vary once 
neutrophil engraftment occurs. As patients are generally no longer hospitalized following 
neutrophil engraftment, there may be less vigilance resulting in some delay in treatment 
leading to increased mortality. Additional possible factors that may contribute to this 
increased NRM for the BSI-LEP cohort including issues of drug-resistance, increased 
degrees of immunosuppression, and/or patient deconditioning at time of BSI are 
unanswerable within the CIBMTR dataset.
Gudiol et al found that early-onset BSI was mainly related to the presence of neutropenia, 
mucositis and CVC, whereas late-onset BSI mainly affected severely immunosuppressed 
alloHCT recipients with GVHD and corticosteroids.21 In our cohort, only 44% of BSI-VEP 
compared to 61% of BSI-LEP occurred following PBSC transplantation. PBSC 
transplantation is associated with more rapid neutrophil engraftment and increased GVHD 
compared to marrow allografts.22,23 In a recent prospective study comparing rates of 
infections between marrow and peripheral blood HCT from unrelated donors, 47.9% (95% 
CI, 41.5 to 53.9) of BM allograft recipients had infections compared with 32.8% (95% CI, 
27.1 to 38.7) of PBSC allograft recipients (p=0.002). Faster neutrophil engraftment after 
PBSC transplantation may at least partially explain these findings.7
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Acute GVHD is a recognized risk factor for late BSI after alloHCT.14,24,25 Low rates of post 
engraftment BSI and associated mortality have been reported after ex vivo T cell depletion, 
presumably due to lower incidence of GVHD.26 GVHD prevention and treatment contribute 
to the immune compromise in alloHCT patients. However, both the event of infection and 
the event of GVHD have variable onset relative to transplant and are intertwined in 
transplant outcomes. As this analysis sought to examine the impact of bacterial BSI 
occurring by day 100 on transplant outcomes, the event of aGVHD was examined both as an 
event prior to infection or at any time relative to infection in multivariable models (data not 
shown). Notably, there was no difference in significant variables allowing the reporting of a 
multivariable model focused on infection impact. Therefore, our results suggest that the 
increased NRM for patients with BSI-LEP or BSI-both are driven by the infection and not 
concomitant aGVHD alone.
Organisms of BSI differed between the two phases. Streptococcus spp., Enterobacteriaceae, 
and Enterococcus faecium comprised one third of total BSI-VEP. In contrast, Streptococcus 
spp. and Enterobacteriaceae were less frequent in BSI-LEP. CoNS comprised 25% and 33% 
of BSI-VEP and BSI-LEP respectively. The frequency of VRE was similar across the two 
phases. Similar epidemiology has been reported from single center studies26,6. Interestingly, 
we observed a trend toward decrease in all BSI over the years of this study, 2008 through 
2012. A number of advances in supportive care or transplant practices (e.g., more RIC 
alloHCT) may have had an impact on the incidence of BSI and potentially BSI associated 
mortality. This is in the same line with improved outcomes and decreased NRM after 
alloHCT over time.27
Growth factor and supplemental intravenous immunoglobulin (IVIG) use are common for 
various reasons after alloHCT.28,29 In this study, we found that both GCSF and IVIG were 
used significantly higher in patients with any BSI compared to patients without BSI. 
Although counterintuitive, there was likely selection bias with use of these adjunctive 
preventative measures among sicker patients, i.e patients who are high risk to develop 
infections (such as UCB transplantation or ATG use) or already had infection29–31. 
Furthermore, the administration of post-transplant growth factor use and IVIG are only 
captured as given or not, without timing in regards to the infection.
Our study has several limitations. Data on antibiotic prophylaxis or treatment or 
susceptibility (multidrug-resistance) data were not captured in the registry. Lack of this data 
limits understanding of our ability to impact the outcomes of patients with BSI following 
HCT; however, because of the large number of centers and patients, it does not lessen the 
finding that patients with BSI-LEP have inferior outcomes. Ongoing revisions to CIBMTR 
data collection forms should improve our understanding of antibacterial prophylaxis 
strategies but detailed data regarding the treatment of common infections is beyond the 
scope of a transplant registry. Recent studies suggest an association of antibiotic use with 
GVHD and NRM.32 While a correlation of antibiotic exposures before or after BSI with 
mortality is beyond the scope of our study it would be interesting to capture in future 
studies. BSI are not classified using the most updated Centers for Disease Control and 
Prevention (CDC) definitions (i.e., LCBI: MBI-LCBI or CLABSI) due how the data are 
gathered. While we acknowledge these limitations inherent to a registry study, our study has 
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several strengths including a robust sample size from 181 centers from diverse geographic 
locations and reflecting current transplant practices. The inclusion of multiple centers 
provides a diverse population of all ages, stem cell sources, and transplant types; however, it 
also results in a small percentage of missing data. Given that it is less than 5% for nearly all 
pertinent variables, this data is unlikely to change the overall outcomes in this large dataset. 
It is also likely to minimize over or underreporting biases inherent in single center studies. 
Uniform definitions were used for data collection stipulated by CIBMTR and long term 
follow up is ensured.
The comparison of BSI-VEP and BSI-LEP is confounded by the inability to predict prior to 
transplant into which group a patient will ultimately fall. By definition, a patient can only be 
in the BSI-LEP group if no BSI-VEP occurred. Similarly, the patient can only be in the “no 
BSI” group if never developing a BSI in the first 100 days. Furthermore, if a patient dies due 
to BSI-VEP, they do not live long-enough to become eligible for the “Both” category. 
However, if one compares only the patients still alive at day 100, valuable data is lost due to 
early deaths from infection, GVHD, or other causes. Therefore, our analysis and statistical 
methodology attempts to account for all these issues as meaningfully as possible. 
Furthermore, our analysis does not seek to imply that a BSI by day 100 is sole reason for 
inferior survival; instead, we merely demonstrate an association. However, we found no 
difference in the cumulative incidence of cGVHD for the 4 cohorts when analyzing patients 
still alive at day 100. Consequently, it may be other consequences of the BSI (i.e. organ 
dysfunction) or a pre-disposition to later infections (beyond the scope of this analysis) that 
result in the inferior outcomes for patients with a BSI prior to day 100.
In summary, we show that BSI occurring in each phase by D100 post alloHCT is associated 
with increased NRM. BSI-LEP was associated with a higher rate of mortality, indicating that 
neutrophil engraftment was likely critical to the survival of some patients with BSI-VEP, 
especially the ones who did not develop additional BSI-LEP (i.e., patients with BSI-Both). 
Therefore, patients after engraftment should continue to be diligently evaluated for BSIs. 
Further studies should focus on determining the reasons for BSI-LEP, its interaction with 
changes in gut microbiota and modification of prevention and treatment in these patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A.Patients with BSI per documented bacteria involved in BSI-VEP (left column) and BSI-
LEP (middle column) and BSI-Both (right column) within 100 days (presented as %). Most 
of the BSI in VEP and LEP are composed of CoNS, Enterobacteriaceae, and other GPC.
B.Patients with BSI divided by episodes and single organism or polymicrobial infections. 
63% of patients had no BSI whereas 9% of patients had ≥ 2 BSI.
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Figure 2. 
NRM curve for VEP-BSI vs. LEP-BSI vs Both VEP- and LEP-BSI vs. No BSI), starting day 
100 after transplant. Patients with no BSI had a lower NRM.
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Figure 3. 
OS curve for VEP-BSI vs. LEP-BSI vs Both VEP- and LEP-BSI vs. No BSI), starting day 
100 after transplant. Patients with LEP-BSI and Both-BSI especially had worse OS.
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Table 1.
Comparison of clinical characteristics among the four patient groups.
Characteristic
BSI-VEP Total 
n(%)
BSI-LEP Total 
n(%)
BSI-Both Total 
n(%)
No BSI Total 
n(%) P-Value
Number of patients 1,492 824 340 4,472
Number of centers 165 138 105 177
Gender, Male 836 (56) 446 (54) 187 (55) 2,483 (56) 0.840
Age, years median (range) 42 (<1–75) 46 (<1–79) 42 (1–74) 49 (<1–78) <0.001
 ≤10 214 (14) 93 (11) 56 (16) 405 ( 9)
 11–20 179 (12) 98 (12) 40 (12) 338 ( 8)
 21–30 162 (11) 84 (10) 31 ( 9) 430 (10)
 31–40 163 (11) 87 (11) 30 ( 9) 452 (10)
 41–50 222 (15) 120 (15) 58 (17) 725 (16)
 51–60 327 (22) 175 (21) 75 (22) 1,064 (24)
 >60 225 (15) 167 (20) 50 (15) 1,058 (24)
KPS 0.915
 <90 470 (32) 265 (32) 103 (30) 1,392 (31)
 90–100 995 (67) 541 (66) 233 (69) 2,996 (67)
 Missing 27 ( 2) 18 ( 2) 4 ( 1) 84 ( 2)
HCT-CI 0.530
 0 650 (44) 353 (43) 140 (41) 1,927 (43)
 1 224 (15) 114 (14) 55 (16) 649 (15)
 2 159 (11) 91 (11) 44 (13) 536 (12)
 ≥3 433 (29) 321 (30) 95 (28) 1,263 (28)
 Missing 26 ( 2) 13 ( 2) 6 ( 2) 97 ( 2)
Conditioning intensity <0.001
 Myeloablative 1,207 (81) 617 (75) 276 (81) 3,149 (70)
 RIC/NMA 285 (19) 207 (25) 64 (19) 1,323 (30)
TBI dose <0.001
 No TBI 664 (45) 430 (52) 156 (46) 2,480 (55)
 ≤1200 cGy 454 (30) 265 (32) 110 (32) 1,297 (29)
 >1200 cGy 374 (25) 129 (16) 74 (22) 695 (16)
Disease status at HCT <0.001
 AML/ALL Early 596 (40) 325 (39) 132 (39) 1,908 (43)
 AML/ALL Intermediate 378 (25) 192 (23) 88 (26) 884 (20)
 AML/ALL Advanced 254 (17) 115 (14) 57 (17) 613 (14)
 MDS Early 95 ( 6) 70 ( 8) 26 ( 8) 415 ( 9)
 MDS Advanced 156 (10) 119 (14) 34 (10) 630 (14)
  Missing 13 (<1) 3 (<1) 3 (<1) 22 (<1)
Time to AlloHCT, median (range), 
months 7 (<1–313) 7 (<1–173) 7 (1–224) 6 (<1–291) 0.059
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Characteristic
BSI-VEP Total 
n(%)
BSI-LEP Total 
n(%)
BSI-Both Total 
n(%)
No BSI Total 
n(%) P-Value
Donor age, in decades <0.001
 UCB 593 (40) 210 (25) 113 (33) 918 (21)
 Related donor 366 (25) 211 (26) 87 (26) 1,454 (33)
 18–20 43 ( 3) 28 ( 3) 8 ( 2) 148 ( 3)
 21–30 193 (13) 157 (19) 43 (13) 857 (19)
 31–40 118 ( 8) 98 (12) 34 (10) 479 (11)
 41–50 96 ( 6) 63 ( 8) 38 (11) 321 ( 7)
 51–60 28 ( 2) 24 ( 3) 4 ( 1) 97 ( 2)
 Missing 55 ( 4) 33 ( 4) 13 ( 4) 198 ( 4)
Donor-recipient sex match 0.799
 Male-Male 522 (35) 269 (33) 108 (32) 1,554 (35)
 Male-Female 359 (24) 231 (28) 88 (26) 1,128 (25)
 Female-Male 310 (21) 174 (21) 78 (23) 909 (20)
 Female-Female 292 (20) 145 (18) 63 (19) 851 (19)
 Missing 9 (<1) 5 (<1) 3 (<1) 30 (<1)
Donor-recipient CMV status 9 (<1) 5 (<1) 3 (<1) 30 (<1) <0.001
 +/+ 291 (20) 179 (22) 77 (23) 1,043 (23)
 +/− 98 ( 7) 49 ( 6) 27 ( 8) 418 ( 9)
 −/+ 646 (43) 328 (40) 142 (42) 1,627 (36)
 −/− 441 (30) 256 (31) 85 (25) 1,307 (29)
 Both missing 16 ( 1) 12 ( 1) 9 ( 3) 77 ( 2)
Graft type <0.001
 Bone marrow 239 (16) 114 (14) 52 (15) 662 (15)
 PBSC 660 (44) 500 (61) 175 (51) 2,892 (65)
 Umbilical Cord blood 593 (40) 210 (25) 113 (33) 918 (21)
Donor/recipient HLA match <0.001
 Umbilical Cord blood 593 (40) 210 (25) 113 (33) 918 (21)
 HLA-identical siblings 337 (23) 196 (24) 78 (23) 1,379 (31)
 Matched/Mismatched related 5 (<1) 2 (<1) 3 (<1) 20 (<1)
 Haplo-identical 24 ( 2) 13 ( 2) 6 ( 2) 55 ( 1)
 8/8 unrelated 382 (26) 277 (34) 85 (25) 1,558 (35)
 7/8 unrelated 114 ( 8) 98 (12) 42 (12) 401 ( 9)
 <=6/8 unrelated 10 (<1) 5 (<1) 7 ( 2) 27 (<1)
 Unrelated (HLA match information 
missing) 27 ( 2) 23 ( 3) 6 ( 2) 114 ( 3)
ATG/Alemtuzumab as conditioning/
GVHD prophy 0.240
 ATG alone 442 (30) 244 (30) 102 (30) 1,367 (31)
 Alemtuzumab alone 36 ( 2) 9 ( 1) 11 ( 3) 89 ( 2)
 No ATG or Alemtuzumab 1,014 (68) 571 (69) 227 (67) 3,016 (67)
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Characteristic
BSI-VEP Total 
n(%)
BSI-LEP Total 
n(%)
BSI-Both Total 
n(%)
No BSI Total 
n(%) P-Value
GVHD prophylaxis <0.001
 CSA/TAC + MTX ± others 659 (44) 411 (50) 159 (48) 2,398 (54)
 CSA/TAC + MMF ± others 541 (36) 297 (36) 128 (38) 1,393 (31)
 CSA/TAC + others 166 (11) 66 ( 8) 31 ( 9) 392 ( 9)
 CSA/TAC alone 52 ( 3) 20 ( 2) 9 ( 3) 145 ( 3)
 SIRO +/− others (Not TAC/CSA) 3 (<1) 1 (<1) 0 15 (<1)
 ATG/ Alemtuzumab only 0 0 0 7 (<1)
 Ex vivo T-cell depletion 29 ( 2) 10 ( 1) 2 (<1) 26 (<1)
 CD34 selection 19 ( 1) 2 (<1) 5 ( 1) 48 ( 1)
 Cyclophosphamide 20 ( 1) 15 ( 2) 5 ( 1) 81 ( 2)
 Other GVHD prophylaxis 3 (<1) 2 (<1) 1 (<1) 17 (<1)
G-CSF, GM-CSF use, yes 901 (60) 498 (60) 205 (60) 2,379 (53) <0.001
Supplemental IVIG, yes 712 (48) 389 (47) 191 (56) 1,766 (39) <0.001
Year of AlloHCT <0.001
 2008 448 (30) 248 (30) 121 (36) 1,194 (27)
 2009 410 (27) 240 (29) 97 (29) 1,073 (24)
 2010 284 (19) 158 (19) 56 (16) 837 (19)
 2011 177 (12) 98 (12) 42 (12) 642 (14)
 2012 173 (12) 80 (10) 24 ( 7) 726 (16)
Abbreviations: AlloHCT, allogeneic hematapoietic cell transplantation; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; ATG, 
anti-thymocyte globulin; BSI, blood stream infections; CMV, cytomegalovirus; CSA, cyclosporine; G-CSF, granulocyte-colony forming factor; 
GM-CSF, granulocyte,monocyte- colony forming factor; GVHD, graft-versus-host disease; HCT-CI, Hematopoietic cell transplant comorbidity 
index; HLA, human leukocyte antigens; IVIG, intravenous immunoglobulin; KPS, Karnofsky Performance score; LEP, late early phase; MMF, 
mycophenolate mofetil; MTX, methotrexate; NMA, non-myeloablative; PBSC, peripheral blood stem cells; RIC, reduced-intensity conditioning; 
SIRO, sirolimus; TAC, tacrolimus; TBI, total body irradiation WBC, white blood cells; ; VEP, very early phase
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Table 2.
Description of time dependent variables of engraftment and acute GVHD among the four groups.
Variable VEP-BSI LEP-BSI Both-BSI No BSI
Number of patients 1,492 824 340 4,472
Days to first BSI (range) 7 (<1–74) 58 (21–100) 8 (<1–36)
Time to ANC >500, n(%)
 Yes 1,299 (87) 824 340 4,321 (97)
 No 188 (13) 0 0 138 ( 3)
 Missing 5 (<1) 0 0 13 (<1)
Time to ANC >500 days (range) 17 (<1–99) 15 (<1–42) 16 (1–50) 15 (<1–111)
Platelet engraftment >20 ×109/L, n(%)
 Yes 1,103 (74) 721 (88) 277 (81) 4,049 (91)
 No 368 (25) 96 (12) 57 (17) 395 ( 9)
 Missing 21 ( 1) 7 (<1) 6 ( 2) 28 (<1)
Time to platelet >20×109/L, days (range) 27 (1–180) 20 (<1–293) 26 (1–640) 19 (<1–753)
aGVHD, n(%)
 Yes 546 (37) 433 (53) 195 (57) 1,673 (37)
 No 940 (63) 387 (47) 141 (41) 2,783 (62)
 Missing 6 (<1) 4 (<1) 4 ( 1) 16 (<1)
Time to aGVHD diagnosis, days (range) 28 (7–175) 27 (7–176) 26 (7–168) 29 (7–178)
Median follow-up of survivors, months (range) 60 (3–87) 60 (3–81) 60 (12–85) 59 (3–87)
Abbreviations: aGVHD, acute graft-versus-host disease; ANC, absolute neutrophil count; cGVHD, chronic graft-versus-host disease; VEP, very 
early phase; LEP, late early phase
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